Brent A. Stanfield, PhD

Luftig Lab Members

Headshot of Brent A. Stanfield, PhDPostdoctoral Scholar
0045 CARL
Durham, NC 27710
Phone: 919.668.3123
Fax: 919-684-2790
Email: brent.stanfield@duke.edu

 

INTERESTS:

Research Interest: My research interests focus on understanding the complex nature of host pathogen interaction particularly in the relationship between Epstein-Barr virus and the infected B cell. Specifically, I am currently investigating the role of conserved features of the latent membrane protein 1 (LMP1) promoter. Infection of B cells with EBV immediately induces the expression of cellular transcriptional repressive elements particularly Myc. As the infection progresses Myc expression wanes while expression of LMP1 increases. Myc is known to associate with transcription factors that bind to canonical E-box motifs. Phylogenetic analysis of the promoter region of LMP1 demonstrates a strong geographical pressure driving the divergence in this region however elements responsible for regulation of this gene demonstrate strong conservation. We have observed particular conservation in a predicted E-box motif in the promoter of the LMP1. This project has drawn my particular interest because it will utilize my experience generating recombinant herpes viruses and utilizing small animal models to understand the role these regulatory features play in the oncogenesis of EBV.

Personal Interests: In my spare time I try to pursue hobbies that are both educational and fun. I have taken a strong interest in brewing beer. I am also very fond of growing plants. I am lucky to have a wealth of opportunity for both here at Duke and in Durham as a whole.

Publications List:

Courchesne MJ, White MC, Stanfield BA, Frampton AR Jr. Equine herpesvirus type 1-mediated oncolysis of human glioblastoma multiforme cells. J Virol. 2012 Mar;86(5):2882-6. PubMed PMID: 22205738; PubMed Central PMCID: PMC3302254.

Iyer AV, Pahar B, Chouljenko VN, Walker JD, Stanfield B, Kousoulas KG. Single dose of glycoprotein K (gK)-deleted HSV-1 live-attenuated virus protects mice against lethal vaginal challenge with HSV-1 and HSV-2 and induces lasting T cell memory immune responses. Virol J. 2013 Oct 28;10:317. PubMed PMID: 24165088; PubMed Central PMCID: PMC3826548.

Stanfield BA, Stahl J, Chouljenko VN, Subramanian R, Charles AS, Saied AA, Walker JD, Kousoulas KG. A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains. PLoS One. 2014;9(10):e109890. PubMed PMID: 25350288; PubMed Central PMCID: PMC4211657.

Stanfield BA, Kousoulas KG. Herpes Simplex Vaccines: Prospects of Live-Attenuated HSV Vaccines to Combat Genital and Ocular Infections. Current clinical microbiology reports. 2015 Sep; 2(3):125-136. NIHMSID: NIHMS704141; PubMed Central PMCID: PMC4840408.  Haque M, Stanfield BA, Kousoulas KG. Bovine Herpesvirus Type-1 Glycoprotein K (gK) Interacts with UL20 and is Required for Infectious Virus Production. Virology. 2016 Sep 20;499:156-164. PubMed PMID: 27661734

Stanfield BA, Pahar B, Chouljenko VN, Veazey R, Kousoulas KG. Vaccination of rhesus macaques with the live-attenuated HSV-1 vaccine VC2 stimulates the proliferation of mucosal T cells and germinal center responses resulting in sustained production of highly neutralizing antibodies. 2016. Vaccine 35(4): 536-543.

Liu SA, Haque M, Stanfield BA, Andrews FM, Roy AA, Kousoulas KG. A recombinant fusion protein consisting of West Nile virus envelope domain III fused in-frame with equine CD40 ligand induces antiviral immune responses in horses. 2017. Vet Micro 198: 51-58.

Stanfield BA and M. A. Luftig. “Recent advances in understanding Epstein-Barr virus.” F1000 (2017 In-Press).

Liu SA, Stanfield BA, Chouljenko VN, Naidu S, Langohr I, Piero FD, Ferracone J, Roy AA, Kousoulas KG. Intramuscular Immunization of Mice with the Live-Attenuated Herpes Simplex Virus Type-1(HSV-1) Vaccine Strain VC2 Expressing the Equine Herpes Virus-1 (EHV-1) Glycoprotein D (gD) Generates Strong Anti-EHV-1 Immune Responses in Mice. J Virol (2017 In-Press)